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We aimed to investigate the correlation between neutrophil‑to‑lymphocyte ratio (NLR) and 
pathologic complete response (pCR) and survival outcomes in human epidermal growth factor 
receptor 2 (HER2)‑negative breast cancer patients who received neoadjuvant chemotherapy. The 
baseline NLR was evaluated in non‑metastatic, HER2‑negative breast cancer patients who received 
neoadjuvant chemotherapy. Baseline NLR was calculated as absolute neutrophil per lymphocyte 
count from pre‑treatment blood samples. Any value ≥ 2.74 was considered to be a high NLR. In the 
1,097 patients studied, 272 (24.4%) had high NLR and 825 (75.6%) had low NLR. The high NLR was an 
independent factor for pCR (OR 0.595; 95% CIs 0.398–0.890; P = 0.011). Furthermore, high NLR was a 
significant independent parameter affecting DFS (HR 2.298; 95% CIs 1.691–3.124; P < 0.001) and OS 
(HR 1.905; 95% CIs 1.167–3.108; P = 0.010). Regardless of the baseline NLR, survival outcomes were 
excellent in patients who achieved pCR, but high NLR was associated with worse survival for patients 
with residual invasive disease. Our study showed that NLR was predictive for treatment response 
and a prognostic factor in patients with HER2‑negative breast cancer who received neoadjuvant 
chemotherapy. Moreover, we identified that high NLR was associated with poor survival outcomes in 
patients who did not achieve pCR.
Neoadjuvant chemotherapy before definitive cancer surgery is increasingly being accepted as a treatment for 
breast  cancer1. Neoadjuvant chemotherapy has survival outcomes equivalent to those of adjuvant  chemotherapy2,3, 
but also has the following advantages: it can increase the rate of breast-conserving surgery by reducing the size 
and extent of locally advanced tumors, control occult micro-metastasis, and estimate sensitivity to treatment 
 regimen4,5. Besides, it encourages the development and approval of new agents by allowing rapid assessment 
of drug efficacy in neoadjuvant  trials6. To date, pathologic complete response (pCR) following the reception of 
neoadjuvant chemotherapy has been suggested as a surrogate marker for a long-term clinical  benefit7–9. In par-
ticular, patients with HER2-positive breast cancer or triple-negative breast cancer (TNBC) who achieved pCR 
show improved survival than those with residual invasive  disease10.
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Over the past decades, it has been repeatedly reported that the host’s immune system is an essential factor 
in determining clinical outcomes in breast  cancer11,12. The neutrophil-to-lymphocyte ratio (NLR), which is a 
peripheral blood-based parameter that can be measured easily, has been identified as a factor that reflects the 
host’s immune system. A high neutrophil level has been implicated to play a pivotal role in carcinogenesis and 
disease progression by enhancing angiogenesis, inhibiting cancer cell apoptosis, and reducing the adhesion of 
the extracellular  matrix13–15. Moreover, neutrophils suppress the activated T cells, the cytolytic activity of lym-
phocytes, and natural killer  cells16, whereas lymphocytes are known to up-regulate anti-cancer  effects17. There 
is growing evidence that a high NLR is associated with poor response to  chemotherapy18,19 and unfavorable 
prognosis in breast  cancer20–24. However, the predictive or prognostic value of NLR in breast cancer patients 
who were treated with neoadjuvant chemotherapy remains controversial.
The current study aimed to investigate the relationship between pre-treatment NLR and clinical outcomes in 
HER2-negative breast cancer patients who received neoadjuvant chemotherapy. We explored whether NLR had 
a bearing on the survival outcomes of patients who attained pCR and those who did not.
Results
Baseline characteristics. In total, 1,097 HER2-negative breast cancer patients were studied. The median 
age was 47 (range 20–84). Of these patients, 825 (75.2%) were assigned to the low NLR group (NLR < 2.74) 
and 272 (24.8%) to the high NLR group (NLR ≥ 2.74). The baseline characteristics per the NLR status are listed 
in Table 1. The high NLR group contained a significantly younger population (45 vs. 48, p < 0.001) and higher 
clinical T stages and Ki-67 levels than the low NLR group (Table 1). Besides, the high NLR group received less 
anthracycline-cyclophosphamide followed by taxane chemotherapy than the high NLR group (Table 1).
Table 1.  Baseline characteristics. NLR neutrophil to lymphocyte ratio, ER estrogen receptor, PR progesterone 
receptor, cT clinical T stage, cN clinical N stage, pCR pathologic complete response, AC-T doxorubicin 
and cyclophosphamide followed by taxane, AC doxorubicin and cyclophosphamide, AT doxorubicin and 
taxane. *Missing values. † Others: cyclophosphamide, doxorubicin, 5-fluorouracil (CAF); cyclophosphamide, 
methotrexate, 5-fluorouracil (CMF); taxane; taxane plus carboplatin.
NLR < 2.74 (N = 825) NLR ≥ 2.74 (N = 272) Total (N = 1,097) p-value
Age (median, range) 48 (20–84) 45 (22–76) 47 (20–84)  < 0.001
Histologic type 0.407
IDC 771 (93.5%) 258 (94.9%) 1,029 (93.8%)
Others 54 (6.5%) 14 (5.1%) 68 (6.2%)
ER 0.067
Positive 483 (58.5%) 142 (52.2%) 625 (57.0%)
Negative 342 (41.5%) 130 (47.8%) 472 (43.0%)
PR 0.752
Positive 370 (44.8%) 119 (43.8%) 489 (44.6%)
Negative 455 (55.2%) 149 (56.3%) 608 (55.4%)
Subgroup 0.113
HR+HER2− 491 (59.5%) 147 (54.0%) 638 (58.2%)
TNBC 334 (40.5%) 125 (46.0%) 459 (41.8%)
Ki-67* 0.010
< 14 143 (34.7%) 34 (23.1%) 177 (31.7%)
≥ 14 269 (65.3%) 113 (76.9%) 382 (68.3%)
cT 0.025
1 125 (15.2%) 28 (10.3%) 153 (13.9%)
2 558 (67.6%) 181 (66.5%) 739 (67.4%)
3 142 (17.2%) 63 (23.2%) 205 (18.7%)
cN 0.444
Negative 128 (15.5%) 37 (13.6%) 165 (15.0%)
Positive 697 (84.5%) 235 (86.4%) 932 (85.0%)
pCR 0.033
No 635 (77.0%) 226 (83.1%) 861 (78.5%)
Yes 190 (23.0%) 46 (16.9%) 236 (21.5%)
Regimen 0.009
AC-T 661 (80.1%) 196 (72.1%) 857 (78.1%)
AC 26 (3.2%) 10 (3.7%) 36 (3.3%)
AT 113 (13.7%) 47 (17.3%) 160 (14.6%)
Others† 25 (3.0%) 19 (7.0%) 44 (4.0%)
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Of all patients, 638 (58.2%) were hormone receptor (HR)-positive, having HER2-negative breast cancer 
(HR+HER2−), and 459 (41.8%) had triple-negative breast cancer (TNBC). The patients with TNBC were younger 
and had higher clinical T stages and Ki-67 levels than those with HR+HER2− breast cancer (Supplementary 
Table 1). There was no difference in NLR between the two groups.
pCR rate according to NLR. Baseline NLR was associated with response to neoadjuvant systemic therapy: 
pCR was achieved in 190 (23.0%) of the 825 low NLR patients and in 46 (16.9%) of the 272 high NLR patients 
(P = 0.033; Fig. 1). Elevated NLR was significantly associated with low pCR in univariable analysis (OR 0.680; 
95% CIs 0.476–0.971; P = 0.034; Table 2), and it remained a significant factor in a multivariable analysis adjusted 
for other clinicopathologic parameters (OR 0.595; 95% CIs 0.398–0.890; P = 0.011; Table 2).
In the HR+HER2− breast cancer patients, pCR was achieved in 44 (9.0%) of 491 low NLR patients and in 6 
(4.1%) of 147 high NLR patients (P = 0.053; Fig. 1). In the multivariable analysis, the patients with elevated NLR 
tended have low pCR rates, but this was not statistically significant (OR 0.433; 95% CIs 0.178–1.056; P = 0.066; 
Supplementary Table 2). In TNBC patients, pCR was achieved in 146 (43.7%) of 334 low NLR patients and in 40 
(32.0%) of 125 high NLR patients (P = 0.023; Fig. 1). The multivariable analysis showed that high NLR tended 
to be associated with low pCR rate, although it was not statistically significant (OR 0.645; 95% CIs 0.408–1.020; 
P = 0.061; Supplementary Table 2).
Survival outcomes according to NLR. During the median follow up period of 56  months (range 
5–152  months), patients with low NLR had a significantly longer DFS and OS than those with high NLR 
(Fig. 2A,B). In HR+HER2− breast cancer patients, those with low NLR had a significantly longer DFS than those 
with high NLR, although there was no difference in OS between both groups (Fig. 2C,D). In contrast, in TNBC 
patients, those with low NLR had significantly longer DFS and OS than those with high NLR (Fig. 2E,F).
In both univariable and multivariable analyses, the baseline NLR was an independent prognostic factor 
for DFS (HR 2.604; 95% CIs 1.927–3.518; P < 0.001, HR 2.298; 95% CIs 1.691–3.124; P < 0.001, respectively; 
Table 3) and OS (HR 2.235; 95% CIs 1.391–3.591; P = 0.001, HR 1.905; 95% CIs 1.167–3.108; P = 0.010, respec-
tively; Table 3). Similarly, in TNBC, the univariable and multivariable analyses showed that the baseline NLR 
was an independent prognostic factor for DFS (HR 2.737; 95% CIs 1.759–4.259; P < 0.001, HR 2.491; 95% CIs 
1.599–3.882; P < 0.001, respectively; Supplementary Table 3) and OS (HR 2.298; 95% CIs 1.269–4.161; P = 0.006, 
HR 2.053; 95% CIs 1.132–3.725; P = 0.018, respectively; Supplementary Table 3). In HR+HER2− breast cancer, 
the baseline NLR was significantly associated with DFS in univariable analysis (HR 2.444; 95% CIs 1.617–3.692; 
P < 0.001) and multivariable analysis (HR 2.323; 95% CIs 1.537–3.511; P < 0.001; Supplementary Table 3), but 
not with OS (Supplementary Table 3).
Survival outcomes according to NLR and pCR. Our results also showed that patients with pCR had 
better survival outcomes than those with residual invasive disease (Supplementary Fig.  1). When combined 
NLR and pCR analysis was performed, patients who achieved pCR had better survival rates in both HR+HER2− 
breast cancer and TNBC cases than those with residual invasive disease, regardless of baseline NLR status. Nota-
bly, the survival rates varied significantly in patients with residual invasive disease based on baseline NLR status. 
We were able to identify the patients with high NLR and residual invasive disease as a high-risk group who had a 
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worse DFS (Fig. 3A), and OS (Fig. 3B) than the other groups. In HR+HER2− patients, those with high NLR and 
residual invasive disease were significantly associated with poor DFS (Fig. 3C), but not OS (Fig. 3D). In TNBC 
patients, those with high NLR and residual invasive disease had adverse DFS (Fig. 3E), and OS (Fig. 3F).
Discussion
Recently, high tumor-infiltrating lymphocytes (TILs) has been identified as biomarker related to pCR and better 
clinical outcomes in patients with breast cancer who received neoadjuvant  chemotherapy25. These data suggest 
that the immune system might have an important role in terms of treatment response and prognosis. Similar to 
TILs, we found that the NLR was an independent factor for pCR and survival in patients with HER2-negative 
breast cancer who received neoadjuvant chemotherapy. Nevertheless, the precise mechanism underlying the 
impact of NLR on chemotherapy response and clinical outcomes in breast cancer has been unclear. Previous 
studies speculated several potential mechanisms. The high NLR can be caused by neutrophilia and/or lympho-
penia linked to the inflammatory response and depletion of anti-tumor immune function, which in turn leads 
to tumor  progression26–28. Few data revealed that the high NLR was associated with increased peri-tumoral 
macrophages, which contribute to chemotherapy  resistance29,30. In addition, anthracycline and taxane-based 
chemotherapy that most patients received in this study provide an anti-cancer immune response via triggering 
immunogenic cell  death31, which may affect the difference in chemotherapy efficacy according to NLR. Further 
studies to verify this issue are warranted.
The differences in pCR and survival according to baseline NLR were more pronounced in TNBC subype than 
in HR+HER2− breast cancer subtype. The previous studies demonstrated that TNBC was more immunogenic 
compared to other subtypes of breast cancer, and higher pre-treatment TILs were correlated with increased pCR 
rates, and improved survival in TNBC patients treated with neoadjuvant  chemotherapy25,32. Also, the adjuvant 
chemotherapy trials in TNBC have shown that TILs are strongly associated with improved  survival33,34. Similar 
to our findings, several lines of evidence described that the pre-treatment NLR was predictive of the efficacy of 
neoadjuvant chemotherapy and disease outcomes in  TNBC19,35,36. Compared to these recent relatively small-
cohort studies of about a hundred patients with TNBC, our research has the advantage of having analyzed a 
larger cohort.
Unlike in TNBC, the predictive and prognostic role of immune-related markers, including TIL and NLR, 
remain unclear in HR+HER2− breast  cancer20–22. Furthermore, a pooled analysis described that the patients with 
high TIL were inversely associated with survival in HR+HER2− breast  cancer25. However, most of the previous 
studies that investigated the prognostic role of NLR in HR+HER2− breast cancer had the limitation of using small 
Table 2.  Odds ratios (ORs) and 95% confidential intervals (CIs) for pCR in all patients. pCR pathologic 
complete response, NLR neutrophil to lymphocyte ratio, cT clinical T stage, cN clinical N stage, ER estrogen 
receptor, PR progesterone receptor, AC-T doxorubicin and cyclophosphamide followed by taxane, AC 
doxorubicin and cyclophosphamide, AT doxorubicin and taxane. *Others: cyclophosphamide, doxorubicin, 
5-fluorouracil (CAF); cyclophosphamide, methotrexate, 5-fluorouracil (CMF); taxane; taxane plus carboplatin.
Univariate Multivariate
OR (95% CIs) P-value OR (95% CIs) P-value
Age 0.996 (0.982–1.011) 0.62 0.992 (0.977–1.008) 0.336
NLR
< 2.74 Ref Ref
≥ 2.74 0.680 (0.476–0.971) 0.034 0.595 (0.398–0.890) 0.011
cT stage 0.002 < 0.001
1 Ref Ref
2 1.320 (0.856–2.036) 0.209 0.804 (0.489–1.324) 0.392
3 0.596 (0.336–1.056) 0.076 0.327 (0.172–0.621) 0.001
cN stage
Negative Ref Ref
Positive 0.407 (0.285–0.582) < 0.001 0.583 (0.385–0.883) 0.011
ER
Positive Ref Ref
Negative 7.713 (5.462–10.892) < 0.001 5.017 (3.033–8.299) < 0.001
PR
Positive Ref Ref
Negative 7.515 (5.034–11.220) < 0.001 2.283 (1.289–4.044) 0.005
Regimen 0.002 < 0.001
AC-T Ref Ref
AC 0.516 (0.198–1.345) 0.176 0.407 (0.142–1.168) 0.095
AT 0.381 (0.225–0.644) < 0.001 0.308 (0.174–0.544) < 0.001
Others* 0.941 (0.457–1.939) 0.870 0.741 (0.333–1.651) 0.463
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cohorts and short follow up periods of less than 5 years. In contrast, the current study assessed a relatively large 
number of HR+HER2− breast cancer patients who received neoadjuvant chemotherapy and discovered that low 
NLR was related to favorable survival rates in terms of DFS. Given that disease-related events occur steadily after 
5 years of diagnosis in HR+HER2− breast cancer  patients37, and the median follow up period was about 5 years 
in this study, further research with longer term follow up is needed to validate these findings.
It is well known that the prognosis is poor in patients with residual tumor after neoadjuvant  therapy10. The 
CREATE-X and KATHERINE trials have already demonstrated that new therapeutic approaches, such as the 
addition of further chemotherapy or the change of HER2-targeted therapy, conferred a survival benefit in patients 
with residual invasive disease after neoadjuvant  therapy38,39. Besides, in our study, baseline NLR provided an 
additional prognostic information in patients with residual disease after neoadjuvant chemotherapy in line with 
previous  study40: Even when limited to patients with residual invasive disease after neoadjuvant chemotherapy, 
high NLR was related to poor survival outcomes. These results suggest that patients with poor treatment response 
and an impaired immune system should be considered as a high-risk group for adverse prognosis, and there is 
a need for a new therapeutic strategy to improve survival outcomes in these patients.
The major limitation of our study is its retrospective nature. Particularly, the histologic grade, lymphovas-
cular invasion, and Ki-67 levels, which could be factors associated with pCR and prognosis, were not routinely 
Figure 2.  Prognostic ability of the baseline NLR. Kaplan–Meier curves of (A) DFS in all patients, (B) OS in all 
patients, (C) DFS in HR+HER2− breast cancer, (D) OS in HR+HER2− breast cancer, (E) DFS in TNBC, (F) OS 
in TNBC, DFS disease-free survival, OS overall survival, HR hormone receptor, HER2 human epidermal growth 
factor receptor 2, TNBC triple-negative breast cancer. All graphs were prepared using the software Graphpad 
Prism Version 8 (GraphPad Software, USA, https ://www.graph pad.com/scien tific -softw are/prism /).
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evaluated in pre-treatment biopsy samples. Although the Ki-67 was estimated in about half of whole cohort, 
and NLR was still an independent factor related to pCR, DFS, and OS in these patients (Supplementary Table 4 
and 5). Also, we could not analyze the relationship between NLR and TILs, which represent the immune sys-
tem in the tumor microenvironment. Currently, NLR cutoff value has not been established, and the acceptable 
discriminant point varies across studies. In this analysis, NLR cutoff point was set at 2.74, which is within the 
1.8–4.0 range reported by the previous  studies19–22, and this value should be validated by independent cohorts.
In conclusion, baseline NLR may be a potential biomarker of host immunity for predicting response to 
neoadjuvant chemotherapy and prognosis in HER2-negative breast cancer patients. Furthermore, we identified 
that elevated baseline NLR was associated with worse clinical outcomes among patients with residual invasive 
disease after neoadjuvant chemotherapy. Our findings suggest that new therapeutic strategies are needed to 
improve survival in these patients.
Methods
Study population. We retrospectively analyzed the data of non-metastatic, HER2-negative breast cancer 
patients who received neoadjuvant chemotherapy followed by surgery between January 2007 to June 2018 at 
Gangnam Severance Hospital and Severance Hospital. Medical records were reviewed to collect patient data 
like age and clinicopathologic data such as medical history, estrogen receptor (ER) status, progesterone receptor 
Table 3.  Hazard ratios (HRs) and 95% confidential intervals (CIs) for disease-free survival and overall 
survival in all patients. NLR neutrophil to lymphocyte ratio, cT clinical T stage, cN clinical N stage, ER 
estrogen receptor, PR progesterone receptor, pCR pathologic complete response, AC-T doxorubicin and 
cyclophosphamide followed by taxane, AC doxorubicin and cyclophosphamide, AT doxorubicin and 
taxane. *Others: cyclophosphamide, doxorubicin, 5-fluorouracil (CAF); cyclophosphamide, methotrexate, 
5-fluorouracil (CMF); taxane; taxane plus carboplatin.
Variables
Disease-free survival Overall survival
Univariate Multivariate Univariate Multivariate
HRs (95% CIs) P-value HRs (95% CIs) P-value HRs (95% CIs) P-value HRs (95% CIs) P-value








< 2.74 Ref Ref Ref Ref
≥ 2.74 2.604 (1.927–3.518)  < 0.001
2.298 (1.691–





cT stage 0.042 0.247 0.108 0.216
1 Ref Ref Ref Ref















Negative Ref Ref Ref Ref








Positive Ref Ref Ref Ref




6.435)  < 0.001
5.457 (2.463–
12.092)  < 0.001
PR
Positive Ref Ref Ref Ref








Yes Ref Ref Ref Ref
No 3.658 (2.034–6.579)  < 0.001
4.553 (2.483–





Regimen 0.033 0.723 0.110 0.914
AC-T Ref Ref Ref Ref
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(PR) status, human epidermal growth factor 2 (HER2) status, Ki-67 levels, clinical T stage, clinical N stage, pCR, 
and laboratory data. The clinical stages were determined per the 7th edition of the American Joint Committee 
on Cancer guidelines.
The exclusion criteria for this study were: (i) a history of cancer including ductal carcinoma in situ or invasive 
breast cancer, and other malignancies, (ii) presence of bilateral breast lesions, (iii) presence of inflammatory 
breast cancer, (iv) lack of patient information such as baseline NLR, and (v) presence of a hematologic disorder or 
systemic inflammatory disease. Eventually, 1,097 patients were studied (Fig. 4) and of this number, 1,017 (92.3%) 
received anthracycline-taxane-based chemotherapy. The details chemotherapy regimens are given in Table 1.
Following the Good Clinical Practice guidelines and the Declaration of Helsinki, our study was approved by 
the Institutional Review Board at Severance Hospital, Yonsei University, Seoul, Republic of Korea (Local IRB 
number: 3-2018-0191). The need for informed consent was waived under the approval of the IRB due to the 
retrospective design.
Baseline neutrophil‑to‑lymphocyte ratio (NLR). Baseline NLR was calculated as neutrophil count per 
lymphocyte count from blood samples taken within 2 weeks before initiation of neoadjuvant chemotherapy. The 
Figure 3.  Prognostic ability of the combined with pCR and baseline NLR. Kaplan–Meier curves of (A) DFS in 
all patients, (B) OS in all patients, (C) DFS in HR+HER2− breast cancer, (D) OS in HR+HER2− breast cancer, 
(E) DFS in TNBC, (F) OS in TNBC. DFS disease-free survival, OS overall survival, HR hormone receptor, HER2 
human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, NS not significant. *P < 0.05; 
**P < 0.001. All graphs were prepared using the software Graphpad Prism Version 8 (GraphPad Software, USA, 
https ://www.graph pad.com/scien tific -softw are/prism /).
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cutoff point of 2.74 was decided as the maximum area under curve value using receiver operating characteristics 
curve for predicting disease-free survival (DFS); hence, patients were assigned into two groups: the high NLR 
group (≥ 2.74) and the low NLR group (< 2.74). An about a quarter of our cohort were on this basis classified as 
high NLR.
Pathology. In our immunohistochemistry (IHC) study, core needle biopsy samples were stained using 
appropriate antibodies specific for four markers: ER (1:100 dilution, clone 6F11; Novocastra, Newcastle upon 
Tyne, UK), PR (clone 16; Novocastra, UK), HER2 (4B5 rabbit monoclonal antibody; Ventana Medical Systems, 
Tucson, AZ, USA), and Ki-67 (MIB-1; Dako, Glostrup, Denmark). ER- and PR-positive were defined as a cutoff 
value of ≥ 1% positively stained  nuclei41, or according to the modified Allred system: positive, Allred scores 
2–8,and negative, Allred scores  042. The HER2 status was defined as positive with a score of 3+, and negative with 
a score of 0 or 1+. Tumors with scores of 2+ were sent for fluorescent in situ hybridization analysis according to 
the protocol given by the supplier (PathVysion kit; Vysis, Downers Grove, IL, USA, or HER2 inform; Ventana)43. 
Staining positive for the nuclear antigen Ki-67 was evaluated in a quantitatively and visually way using light 
microscopes, and the positive tumor cell percentage was reported as the Ki-67 labeling index (LI)44. We consid-
ered Ki-67 levels ≥ 14% as  high45.
Statistical analysis. Continuous variables were compared using Student’s t-test, and categorical variables 
were compared by the Chi-square test or Fisher’s exact test. The pCR was defined as no evidence of invasive 
cancer residue in both breast and axillary lymph nodes (ypT0/is, ypN0) based on the pathologic evaluation of 
the surgical specimen after neoadjuvant  chemotherapy46. Multivariable analysis for pCR was performed using 
a binary logistic regression model. Odds ratios (ORs) and 95% confidence intervals (CIs) with two-sided P-val-
ues were given. DFS was measured as the period between breast cancer diagnosis and first tumor recurrence, 
including locoregional recurrence, and distant recurrence. The overall survival (OS) was measured as the period 
between breast cancer diagnosis to death by any cause. The Kaplan–Meier method was used to calculate DFS and 
OS, and the results between groups were compared using the log-rank test. Multivariable analysis for survival 
outcomes was carried out using a Cox proportional hazards model. All analyses were performed using SPSS ver-
sion 23 (SPSS; Chicago, IL, USA), and statistical significance was defined as P-value < 0.05.
Consent for publication. All authors have given consent for publication.
Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on 
request.
Figure 4.  Study population.
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